Page 5 - Dental_11_2021
P. 5

My dental surgery patients

        need pain relief that

        acts fast…and lasts…                         1

        …  I prescribe once-daily                      2,3

          ARCOXIA /EXINEF                           ®


        ARCOXIA /EXINEF  90 mg OFFERS…

                                        …FAST ONSET

                                             OF ACTION                1
                                                                                             28 min

                                                                 ®                                              ®

        Indicated for the treatment of moderate to severe acute                      RECOMMENDED DOSE

        post-operative pain associated with dental surgery               2,3            90 mg ONCE DAILY

        REFERENCES: 1. Daniels SE, Bandy DP, Christensen SE, et al., Evaluation of the Dose Range of Etoricoxib in an Acute Pain Setting Using the Postoperative Dental Pain Model. Clin J Pain. 2011;27(1).
        2. Approved ARCOXIA® package insert, March 2020.  3. Approved EXINEF® package insert, May 2020.
        INDICATIONS: ARCOXIA®/EXINEF® is indicated for: symptomatic relief of osteoarthritis (OA) and rheumatoid arthritis (RA); treatment of ankylosing spondylitis (AS); treatment of acute gouty arthritis; short term
        relief of acute pain, treatment limited to a maximum period of 8 days; treatment of primary dysmenorrhoea; treatment of moderate to severe acute post-operative pain associated with dental surgery.
        SELECTED SAFETY INFORMATION: CONTRAINDICATIONS: Known hypersensitivity to etoricoxib or to any of the excipients of ARCOXIA®/EXINEF®, patients who have developed signs of asthma, acute rhinitis, nasal polyps, angioedema or urticaria following the
        administration of aspirin or other non-steroidal anti-inflammatory drugs (NSAIDs) including ARCOXIA®/EXINEF®. Active peptic ulceration or active gastrointestinal (GI) bleeding, severe hepatic dysfunction (Child-Pugh score greater than 9 or serum albumin less than
        25 g/L), severe renal impairment (eCrCl less than 30 mL/min), uncontrolled hypertension, pregnancy and lactation, children and adolescents under 16 years of age, inflammatory bowel disease, congestive heart failure (NYHA II – IV), established ischaemic heart disease,
        peripheral arterial disease and/or cerebrovascular disease, perioperative analgesia in the setting of coronary artery bypass surgery (CABG), concomitant administration with ARCOXIA®/EXINEF® may lead to toxic blood concentrations of lithium and digoxin (approximate
        increase of 33 % in digoxin C max in healthy volunteers). WARNINGS AND SPECIAL PRECAUTIONS: ARCOXIA®/EXINEF® may predispose patients to cardiovascular events, gastrointestinal events or cutaneous reactions which may be fatal. Long-term administration
        of NSAIDs such as ARCOXIA®/EXINEF®, has resulted in renal papillary necrosis and other renal injury. Selective COX-2 inhibitor class of medicines, such as ARCOXIA®/EXINEF®, are associated with an increased risk of arterial thrombotic events (especially myocardial
        infarction (MI) and stroke). As the cardiovascular risks may increase with dose and duration of exposure, the shortest duration possible and the lowest effective daily dose should be used. Caution should be used when initiating treatment with ARCOXIA®/EXINEF® in patients
        with dehydration. It is advisable to rehydrate patients prior to starting therapy with ARCOXIA®/EXINEF®. Caution should be exercised in patients with history of cardiac failure, left ventricular dysfunction or hypertension, and in patients with pre-existing oedema from any
        other reason. ARCOXIA®/EXINEF® is not a substitute for aspirin for cardiovascular prophylaxis because of its lack of effect on platelets. Because ARCOXIA®/EXINEF® does not inhibit platelet aggregation, antiplatelet therapies should not be discontinued. Concomitant
        administration of low-dose aspirin with ARCOXIA®/EXINEF® increases the rate of gastrointestinal adverse effects. Serious skin reactions, some of them fatal, including exfoliative dermatitis, Stevens-Johnson syndrome and toxic epidermal necrolysis have been reported in
        association with the use of selective COX-2 inhibitors such as ARCOXIA®/EXINEF®. When using ARCOXIA®/EXINEF® in the elderly and in patients with renal, hepatic or cardiac dysfunction, medically appropriate supervision should be intensified. Upper gastrointestinal
        complications: perforations, ulcers or bleedings (PUBs), some of them resulting in a fatal outcome, have occurred in patients treated with ARCOXIA®/EXINEF® Elevations of alanine aminotransferase (ALT) and/or aspartate aminotransferase (AST) have been reported in
        approximately 1% of patients in clinical trials treated for up to 1 year with ARCOXIA®/EXINEF® 60 mg and 90 mg daily. Contains lactose. Patients with the rare hereditary conditions of galactose intolerance e.g. galactosaemia, Lapp lactase deficiency, glucose-galactose
        malabsorption or fructose intolerance should not take ARCOXIA®/EXINEF®. SIDE EFFECTS: Very common (≥ 1/10) and common (≥ 1/100, < 1/10) side effects: Post-dental extraction alveolar osteitis (dry socket), oedema/fluid retention, dizziness, headache, palpitations,
        hypertension, gastrointestinal disorders (e.g. abdominal pain, flatulence, heartburn), diarrhoea, dyspepsia, epigastric discomfort, nausea, ecchymosis, asthenia/fatigue, flu-like disease, increased ALT and AST.
        For full prescribing information refer to the package insert approved by the Medicines Regulatory Authority.
                   MSD (Pty) Ltd (Reg. No. 1996/003791/07),                            Co-marketed by: Organon South Africa (Pty) Ltd
                   Private Bag 3, Halfway House 1685 I Tel: 011 655 3000  I  Email:
        S3  ARCOXIA® – Reg. No’s: 30 mg – 44/3.1/0063, 60 mg – 37/3.1/0399, 90 mg – 37/3.1/0400, 120 mg – 37/3.1/0401. Each ARCOXIA tablet contains 30 mg, 60 mg, 90 mg or 120 mg of etoricoxib.
        S3  EXINEF® – Reg. No’s: 30 mg – 44/3.1/0898, 60 mg – 44/3.1/0899, 90 mg – 44/3.1/0900, 120 mg – 44/3.1/0901. Each EXINEF tablet contains 30 mg, 60 mg, 90 mg or 120 mg of etoricoxib.
        Copyright © 2021 Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA. All rights reserved.         ZA-CXB-110004 11/23
   1   2   3   4   5   6   7   8   9   10